International Emerging Infections Program, Centers for Disease Control and Prevention, Mbagathi Road, off Mbagathi Way, Nairobi, Kenya.
BMC Infect Dis. 2010 Jun 23;10:186. doi: 10.1186/1471-2334-10-186.
Although causing substantial morbidity, the burden of pneumococcal disease among older children and adults in Africa, particularly in rural settings, is not well-characterized. We evaluated pneumococcal bacteremia among 21,000 persons > or =5 years old in a prospective cohort as part of population-based infectious disease surveillance in rural western Kenya from October 2006-September 2008.
Blood cultures were done on patients meeting pre-defined criteria--severe acute respiratory illness (SARI), fever, and admission for any reason at a referral health facility within 5 kilometers of all 33 villages where surveillance took place. Serotyping of Streptococcus pneumoniae was done by latex agglutination and quellung reaction and antibiotic susceptibility testing was done using broth microdilution. We extrapolated incidence rates based on persons with compatible illnesses in the surveillance population who were not cultured. We estimated rates among HIV-infected persons based on community HIV prevalence. We projected the national burden of pneumococcal bacteremia cases based on these rates.
Among 1,301 blood cultures among persons > or =5 years, 52 (4%) yielded pneumococcus, which was the most common bacteria isolated. The yield was higher among those > or =18 years than 5-17 years (6.9% versus 1.6%, p < 0.001). The highest yield was for inpatients with SARI (10%), compared with SARI outpatients (3%) and acute febrile outpatients (1%). Serotype 1 pneumococcus was most common (42% isolates) and 71% were serotypes included in the 10-valent pneumococcal conjugate vaccine (PCV10). Non-susceptibility to beta-lactam antibiotics was low (<5%), but to trimethoprim-sulfamethoxazole was high (>95%). The crude rate of pneumococcal bacteremia was 129/100,000 person-years, and the adjusted rate was 419/100,000 person-years. Nineteen (61%) of 31 patients with HIV results were HIV-positive. The adjusted rate among HIV-infected persons was 2,399/100,000 person-years (Rate ratio versus HIV-negative adults, 19.7, 95% CI 12.4-31.1). We project 58,483 cases of pneumococcal bacteremia will occur in Kenyan adults in 2010.
Pneumococcal bacteremia rates were high among persons > or =5 years old, particularly among HIV-infected persons. Ongoing surveillance will document if expanded use of highly-active antiretroviral treatment for HIV and introduction of PCV10 for Kenyan children (anticipated in late 2010) result in substantial secondary benefits by reducing pneumococcal disease in adults.
尽管肺炎球菌疾病会导致大量发病和严重的发病,但其在非洲的儿童和成人(尤其是在农村地区)中的负担却没有得到很好的描述。我们对 2006 年 10 月至 2008 年 9 月在肯尼亚西部农村进行的基于人群的传染病监测中 21,000 名年龄大于或等于 5 岁的人群进行了前瞻性队列研究,评估了他们的肺炎球菌菌血症情况。
对符合以下预定义标准的患者进行血液培养:严重急性呼吸道感染(SARI)、发热和在距所有 33 个村庄 5 公里以内的转诊卫生机构内因任何原因住院的患者。通过乳胶凝集和-Quellung 反应对肺炎链球菌进行血清分型,使用肉汤微量稀释法进行抗生素敏感性试验。我们根据监测人群中未进行培养的具有相容疾病的患者来推断发病率。我们根据社区 HIV 流行率来估计 HIV 感染者的发病率。我们根据这些比率来预测全国范围内肺炎球菌菌血症病例的负担。
在对年龄大于或等于 5 岁的 1301 例血液培养中,52 例(4%)培养出肺炎球菌,这是最常见的分离菌。18 岁及以上患者的分离率(6.9%)高于 5-17 岁患者(1.6%,p <0.001)。住院的 SARI 患者的分离率最高(10%),而 SARI 门诊患者(3%)和急性发热门诊患者(1%)的分离率较低。血清型 1 肺炎球菌最为常见(42%的分离株),且 71%的分离株为包含在 10 价肺炎球菌结合疫苗(PCV10)中的血清型。对β-内酰胺类抗生素的非敏感性较低(<5%),但对磺胺甲恶唑/甲氧苄啶的非敏感性较高(>95%)。肺炎球菌菌血症的粗发病率为 129/100,000 人年,调整后的发病率为 419/100,000 人年。31 例 HIV 结果中有 19 例(61%)为 HIV 阳性。HIV 感染者的调整后发病率为 2399/100,000 人年(与 HIV 阴性成年人相比,比率比为 19.7,95%置信区间 12.4-31.1)。我们预计 2010 年肯尼亚成年人将发生 58,483 例肺炎球菌菌血症。
18 岁及以上人群中肺炎球菌菌血症的发病率较高,尤其是 HIV 感染者。持续监测将记录,如果扩大对 HIV 的高效抗逆转录病毒治疗的使用以及在肯尼亚儿童中引入 PCV10(预计在 2010 年底)是否会通过减少成人中的肺炎球菌疾病而带来实质性的次要益处。